Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Forbes2d
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug’s Latest Approval
The FDA has approved Ozempic for type 2 diabetes, but it’s also known for its use off-label for weight loss. The agency has authorized Novo Nordisk’s Wegovy—which shares the same active ...
Kiplinger7d
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
The topline results from the Phase 1b/2a clinical trial showed that patients treated with Amycretin achieved a body weight loss of 9.7% ... for Development at Novo Nordisk. "The results seen ...
AOL5d
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
Novo Nordisk has been one of the chief ... the company hopes will build on the success of flagship weight-loss treatments Wegovy and Ozempic. Like those injections, the new drug targets gut ...